




Ontruzant[®]
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL

CODING AND BILLING GUIDE FOR *ONTRUZANT*[®] (trastuzumab-dttb)

Programmed with links to help you find the information
you need faster

Before prescribing ONTRUZANT, please read the **Selected Safety Information** on pages 3-6 and the accompanying **Prescribing Information**, including the **Boxed Warning** about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.



Included are lists of codes that may be relevant for ONTRUZANT and its administration. This information is current as of June 2025. The information provided here is compiled from sources believed to be accurate, but Organon makes no representation that it is accurate. Information about Healthcare Common Procedure Coding System (HCPCS) codes is based on guidance issued by the Centers for Medicare & Medicaid Services (CMS) applicable to Medicare Part B and may not apply to other public or private payers. Consult the relevant manual and/or other guidelines for a description of each code to determine the appropriateness of a particular code and for information on additional codes. This information is subject to change. Organon cautions that payer coding requirements vary and can frequently change, so it is important to regularly check with each payer or, where applicable, the Medicare Administrative Contractor, as to payer-specific requirements.

You are solely responsible for determining the appropriate codes and for any action you take in billing. The information provided here is not intended to be definitive or exhaustive, and is not intended to replace the guidance of a qualified professional advisor. Organon and its agents make no warranties or guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. The use of this information does not guarantee payment or that any payment received will cover your costs.

Diagnosis codes should be selected only by a health care professional. Health care professionals are solely responsible for selecting codes that appropriately reflect the patient's diagnosis, the services rendered, and the applicable payers' guidelines. Although CMS has said that an unspecified code may be appropriate in some cases, CMS has advised that you should always code with as much specificity as possible, consistent with the clinical documentation.

Before prescribing ONTRUZANT, please read the Selected Safety Information on pages 3-6 and the accompanying [Prescribing Information](#), including the Boxed Warning about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.



Ontruzant[®]
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL

INDICATIONS AND SELECTED SAFETY INFORMATION

INDICATIONS AND USAGE

Adjuvant Breast Cancer

ONTRUZANT is indicated in adults for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer:

- As part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
- As part of a treatment regimen with docetaxel and carboplatin
- As a single agent following multi-modality anthracycline-based therapy

Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.

Metastatic Breast Cancer

ONTRUZANT is indicated in adults:

- In combination with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer
- As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease

Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.

Metastatic Gastric Cancer

ONTRUZANT is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.

Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.

SELECTED SAFETY INFORMATION

CARDIOMYOPATHY

- **Administration of trastuzumab products can result in subclinical and clinical cardiac failure. The incidence and severity was highest in patients receiving a trastuzumab product with anthracycline-containing chemotherapy regimens.**
- **Evaluate left ventricular function in all patients prior to and during treatment with ONTRUZANT. Discontinue ONTRUZANT treatment in patients receiving adjuvant therapy and withhold ONTRUZANT in patients with metastatic disease for clinically significant decrease in left ventricular function.**

INFUSION REACTIONS; PULMONARY TOXICITY

- **Administration of trastuzumab products can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration of trastuzumab products. Interrupt ONTRUZANT infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue ONTRUZANT for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.**

ER, estrogen receptor; FDA, US Food and Drug Administration; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.

Before prescribing ONTRUZANT, please read the accompanying Prescribing Information, including the Boxed Warning about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.



Ontruzant®
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL

SELECTED SAFETY INFORMATION *(continued)*

EMBRYO-FETAL TOXICITY

- **Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception.**

WARNINGS AND PRECAUTIONS

CARDIOMYOPATHY

- **Administration of trastuzumab products can result in subclinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens. In a pivotal adjuvant breast cancer trial, one patient who developed congestive heart failure (CHF) died of cardiomyopathy.**
- Trastuzumab products can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death.
- Trastuzumab products can also cause asymptomatic decline in left ventricular ejection fraction (LVEF).
- **Discontinue ONTRUZANT treatment in patients receiving adjuvant breast cancer therapy and withhold ONTRUZANT in patients with metastatic disease for clinically significant decrease in left ventricular function.**

CARDIAC MONITORING

- **Evaluate cardiac function prior to and during treatment. For adjuvant breast cancer therapy, also evaluate cardiac function after completion of ONTRUZANT.**
- Conduct a thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan.
- Monitor frequently for decreased left ventricular function during and after ONTRUZANT treatment.
- Monitor more frequently if ONTRUZANT is withheld for significant left ventricular cardiac dysfunction.

INFUSION REACTIONS

- **Administration of trastuzumab products can result in serious and fatal infusion reactions.**
- **Symptoms usually occur during or within 24 hours of administration of trastuzumab products.**
- **Interrupt ONTRUZANT infusion for dyspnea or clinically significant hypotension.**
- **Monitor patients until symptoms completely resolve.**
- **Discontinue ONTRUZANT for infusion reactions manifesting as anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. Strongly consider permanent discontinuation in all patients with severe infusion reactions.**
- Infusion reactions consist of a symptom complex characterized by fever and chills, and on occasion include nausea, vomiting, pain (in some cases at tumor sites), headache, dizziness, dyspnea, hypotension, rash, and asthenia.

MUGA, multigated acquisition.

Before prescribing ONTRUZANT, please read the accompanying Prescribing Information, including the Boxed Warning about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.



Ontruzant®
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL

SELECTED SAFETY INFORMATION *(continued)*

WARNINGS AND PRECAUTIONS *(continued)*

EMBRYO-FETAL TOXICITY

- **Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception.**
- Verify the pregnancy status of females of reproductive potential prior to the initiation of ONTRUZANT.
- Advise pregnant women and females of reproductive potential that exposure to ONTRUZANT during pregnancy or within 7 months prior to conception can result in fetal harm.
- Advise females of reproductive potential to use effective contraception during treatment and for at least 7 months following the last dose of ONTRUZANT.
- Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for ONTRUZANT treatment and any potential adverse effects on the breastfed child from ONTRUZANT or from the underlying maternal condition.

PULMONARY TOXICITY

- **Administration of trastuzumab products can result in serious and fatal pulmonary toxicity**, which includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, noncardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis. Such events can occur as sequelae of infusion reactions.
- Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest, appear to have more severe toxicity.
- Discontinue ONTRUZANT in patients experiencing pulmonary toxicity.

EXACERBATION OF CHEMOTHERAPY-INDUCED NEUTROPENIA

- In randomized, controlled clinical trials, the per-patient incidences of NCI-CTC Grade 3-4 neutropenia and of febrile neutropenia were higher in patients receiving trastuzumab in combination with myelosuppressive chemotherapy as compared to those who received chemotherapy alone. The incidence of septic death was similar among patients who received trastuzumab and those who did not.

DRUG INTERACTIONS

- Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab products' long washout period. If possible, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products. If anthracyclines are used, closely monitor the patient's cardiac function.

NCI-CTC, National Cancer Institute-Common Terminology Criteria.

Before prescribing ONTRUZANT, please read the accompanying Prescribing Information, including the Boxed Warning about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.



Ontruzant®
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL



SELECTED SAFETY INFORMATION *(continued)*

ADVERSE REACTIONS

- The most common adverse reactions associated with trastuzumab products in the adjuvant and metastatic breast cancer setting are fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.
- The most common adverse reactions associated with trastuzumab products in the gastric cancer setting were neutropenia, diarrhea, fatigue, anemia, stomatitis, weight loss, upper respiratory tract infections, fever, thrombocytopenia, mucosal inflammation, nasopharyngitis, and dysgeusia.

Before prescribing ONTRUZANT, please read the accompanying **Prescribing Information**, including the **Boxed Warning** about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.



Ontruzant[®]
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL

CONTENTS

Click the arrows to be taken to specific billing, coding, and product information.

» Indications and Selected Safety Information	3
» National Drug Codes (NDCs) and Billing Codes for ONTRUZANT	8
» NDCs and Packaging Information	8
» Billing Codes	9
» HCPCS Code for ONTRUZANT	9
» Revenue Code—For Use in the Hospital Setting	9
» Current Procedural Terminology (CPT®) Codes for Administration.....	9
» Possible Relevant Diagnosis Codes for Breast Cancer and Gastric Cancer	10
» Coverage and Reimbursement Information	11
» Commercial and Private Payer Coverage	11
» Prior Authorization Checklist	11
» Sample Prior Authorization Letter	11
» Appeal Checklist and Sample Appeal Letter	12
» The Organon Access Program for ONTRUZANT	13
» Sample Claim Forms	14
» References	15

Before prescribing ONTRUZANT, please read the Selected Safety Information on pages 3-6 and the accompanying **Prescribing Information**, including the **Boxed Warning** about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.



Ontruzant[®]
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL

NDCs AND BILLING CODES FOR ONTRUZANT® (trastuzumab-dttb)

Click the Home button to return to the Contents page.



NDCs and Packaging Information

The NDC is typically required when submitting a medical drug claim with a miscellaneous HCPCS code. Please consult with the payer to understand specific billing requirements.

PRODUCT	PACKAGE	NDC EFFECTIVE UPON PRODUCT AVAILABILITY
ONTRUZANT® (trastuzumab-dttb) for injection 150 mg	Carton with one 150-mg vial, single dose	78206-147-01
ONTRUZANT® (trastuzumab-dttb) for injection 420 mg	Carton with one 420-mg vial, multiple dose	78206-148-01

Please note: The NDCs above are the billable NDCs that appear on the cartons. The NDCs on the vial should not be used for billing purposes.

HCPCS, Healthcare Procedure Coding System; NDC, National Drug Code.

Before prescribing ONTRUZANT, please read the Selected Safety Information on pages 3-6 and the accompanying [Prescribing Information](#), including the Boxed Warning about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.



Ontruzant®
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL

NDCs AND BILLING CODES FOR ONTRUZANT® (trastuzumab-dttb) (continued)



Billing Codes

Below is a list of possible codes that could be relevant for ONTRUZANT and its administration. Please consult with the applicable payer to understand the payer's specific billing requirements.

HCPCS Code for ONTRUZANT

HCPCS CODE	DESCRIPTOR
Q5112¹	Injection, trastuzumab-dttb, biosimilar (ONTRUZANT), 10 mg ¹

For questions on billing if a portion of a single-use package is wasted, consult the applicable payer's policy regarding wastage. Record the amount of drug administered and the amount wasted in the patient's medical record. Medicare requires the use of the JW modifier on all claims that include wasted product. Effective July 1, 2023, Medicare requires the use of the JZ modifier on all claims for single-use packages when there are no discarded amounts.²

Revenue Code—For Use in the Hospital Setting

REVENUE CODE	DESCRIPTOR
0636	Pharmacy - drugs requiring detailed coding ³

CPT® Codes for Administration

CPT CODE	DESCRIPTOR
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug ⁴
96415	Chemotherapy administration, intravenous infusion technique; each additional hour ⁴
96417	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour ⁴

HCPCS, Healthcare Procedure Coding System; JW modifier, drug amount discarded/not administered to any patient; JZ modifier, zero drug amount discarded/not administered to any patient; CPT, Current Procedural Terminology. CPT® is a registered trademark of the American Medical Association. Copyright American Medical Association. All rights reserved.

Before prescribing ONTRUZANT, please read the Selected Safety Information on pages 3-6 and the accompanying [Prescribing Information](#), including the Boxed Warning about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.



Ontruzant®
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL

POSSIBLE RELEVANT DIAGNOSIS CODES FOR BREAST CANCER AND GASTRIC CANCER



The following codes are provided as a reference and may be relevant when billing for ONTRUZANT and its administration. Consult the relevant manual and/or other guidelines for a description of each code to determine the appropriateness of its use and for information on additional codes. Diagnosis codes should be selected only by a health care professional. You are solely responsible for determining the appropriate codes and for any action you take in billing. When submitting a claim for ONTRUZANT, always verify coding requirements with the relevant payer. Coding requirements may vary by insurer or plan; please refer to the payer-specific policies to understand what may be covered.

Check with the relevant payer regarding guidance on which diagnoses they will recognize and the applicability of secondary codes. Health care professionals are solely responsible for selecting codes that appropriately reflect the patient's diagnosis, the services rendered, and the applicable payers' guidelines. Providers should document the diagnosis with a sufficiently high degree of specificity based on the information available to enable the identification of the most appropriate code. Although CMS has said that an unspecified code may be appropriate in some cases, CMS has advised that you should always code with as much specificity as possible consistent with the clinical documentation.

Possible Relevant ICD-10-CM Diagnosis Codes for Breast Cancer

Below is a list of possible codes that could be relevant when billing for ONTRUZANT and its administration. Please consult with the applicable payer to understand the payer's specific billing requirements.

Health care professionals are solely responsible for selecting codes that appropriately reflect the patient's diagnosis, the services rendered, and the applicable payer's guidelines.

TYPE	CODE	DESCRIPTION
Diagnosis: ICD-10-CM	C50.011—C50.019, C50.111—C50.119, C50.211—C50.219, C50.311—C50.319, C50.411—C50.419, C50.511—C50.519, C50.611—C50.619, C50.811—C50.819, C50.911—C50.919	Malignant neoplasm of the female breast ⁵
	C50.021—C50.029, C50.121—C50.129, C50.221—C50.229, C50.321—C50.329, C50.421—C50.429, C50.521—C50.529, C50.621—C50.629, C50.821—C50.829, C50.921—C50.929	Malignant neoplasm of the male breast ⁵

Possible Relevant ICD-10-CM Diagnosis Codes for Gastric Cancer

TYPE	CODE	DESCRIPTION
Diagnosis: ICD-10-CM	C16.0—C16.9	Malignant neoplasm of the stomach ⁶

Please see the Indications on page 3.

CMS, Centers for Medicare & Medicaid Services; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification.

Before prescribing ONTRUZANT, please read the Selected Safety Information on pages 3-6 and the accompanying Prescribing Information, including the Boxed Warning about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.



Ontruzant®
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL

COVERAGE AND REIMBURSEMENT INFORMATION

(continued)



The Appeal Checklist and Sample Appeal Letter can help you to understand the documents and information that may be helpful when filing an appeal. As always, you should check for payer-specific requirements.

Appeal Checklist and Sample Appeal Letter

If a claim for a medication is denied, the items listed below may be helpful in the appeals process. It is important to review the denial and the insurer's guidelines, as the required documentation and process for making an appeal will be different depending on the insurer and the patient.

As a first step, ensure that the claim was completed and submitted correctly.

Always verify that:



- The product is covered by the patient's insurer for the patient's diagnosis
- A prior authorization or precertification was obtained, if required by the patient's insurer
- Patient information was recorded correctly (eg, name, date of birth, insurance policy number)
- The product was coded correctly (eg, that the correct code was used to describe the product, that the correct number of units was recorded on the claim, etc)

Prior to initiating the appeal process, it is important to understand the following:

- The reason for denial
- Instructions for initiating the appeal process
- The necessary forms for appeal completion according to the insurer
- Insurer appeal guidelines regarding what documentation to include
- Filing deadlines and payer review timelines

Below is a list of forms and documents that might be helpful when filing an appeal:

- Letter of medical necessity
 - Be sure to note the proposed treatment plan and include the provider ID number in the letter
- Formal letter appealing the denial
- If applicable, the EOB that details the reason for the denial
- Relevant documentation regarding treatment decisions, such as:
 - Previously tried treatments/therapies
 - Patient clinical notes detailing the relevant diagnosis
 - Relevant laboratory results
 - Product package insert/physician label
- Additional relevant documentation (if available) regarding the treatment decision



As a provider, you are solely responsible for billing third-party payers correctly, and you should determine if any payer-specific guidelines apply. The information provided here is general in nature and is not intended to be conclusive or exhaustive, nor is it intended to replace the guidance of a qualified professional advisor. Organon and its agents make no guarantees regarding the timelines or appropriateness of this information for your particular use given the frequent changes in public and private payer billing.

EOB, Explanation of Benefits.

Before prescribing ONTRUZANT, please read the Selected Safety Information on pages 3-6 and the accompanying Prescribing Information, including the Boxed Warning about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.



Ontruzant®
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL



The Organon Access Program for ONTRUZANT


The Organon Access Program can help answer questions about:

- Benefits investigations
- Billing and coding
- Co-pay assistance for eligible patients
- Prior authorizations and appeals
- Referral to the Organon Patient Assistance Program for eligibility determination (provided through the Organon Patient Assistance Program Inc.)
- Product distribution

You can also request to be contacted by a Field Reimbursement Manager.

The Organon Access Program is available online and via a toll-free telephone number.

For more information, visit
organonaccessprogram-ontruzant.com



Call **844-326-2986**,
Monday through Friday,
8 AM to 8 PM ET

Before prescribing ONTRUZANT, please read the Selected Safety Information on pages 3-6 and the accompanying [Prescribing Information](#), including the **Boxed Warning** about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.



Ontruzant[®]
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL

COVERAGE AND REIMBURSEMENT INFORMATION

(continued)



Sample Claim Forms

Click images to download sample claim forms.

Sample UB-04 (also known as CMS 1450) Claim Form for Hospital Outpatient Department Billing: ONTRUZANT® (trastuzumab-dttb) for Injection, for Intravenous Use 21 mg/mL.

Before prescribing ONTRUZANT, please read the accompanying Prescribing Information, including the Boxed Warning.

Note: For purposes of billing, if a portion of a package is unused, consult the applicable payer policy regarding billing. Record the amount of drug administered and the amount retained in the patient encounter's Medication Report for use in the UB-04 form or all bills that include related charges.

Locator 42

- Enter appropriate revenue code for each line item.
- Charges that are billed with HCPCS codes usually require revenue code 02-99.
- Charge requiring attached coding.

Locator 43

- For each line item, enter the appropriate number of units administered (if appropriate) and include the JW modifier if applicable.
- For the line item for ONTRUZANT (trastuzumab-dttb), also enter the drug's brand and generic names.

Locator 44

- Use C5172 to bill for ONTRUZANT (trastuzumab-dttb).
- The inflation time corresponds to DT code 28112. (Some payers may prefer use of HCPCS. Check with the applicable payer.)

Locator 46

- Enter the number of units administered in this field.
- On a separate line, enter the appropriate number of units discarded (if applicable) and include the JW modifier if applicable.
- Note that 1 unit equals 70 mg of ONTRUZANT (trastuzumab-dttb).

Locator 47

- Enter appropriate program codes.

The regulations contained on this form are compiled from sources believed to be accurate for the Medicare Part B program. Ontruzant makes no representation that the information is accurate or that it will comply with the requirements of the Medicare Part B program. Ontruzant makes no representation that the information is accurate or that it will comply with the requirements of the Medicare Part B program. Ontruzant makes no representation that the information is accurate or that it will comply with the requirements of the Medicare Part B program. Ontruzant makes no representation that the information is accurate or that it will comply with the requirements of the Medicare Part B program.

DIG, US Centers for Medicare & Medicaid Services, HCPCS, Healthcare Common Procedure Coding System, DT, Current Procedural Terminology, DT © 2017 American Medical Association. All rights reserved. DT™ is a registered trademark of the American Medical Association, INC. Medicare, Medicaid and Medicare Supplement.

© 2017 Ontruzant. Paper form and electronic billing information is not for sale.

This is a sample UB-04 (CMS-1450) paper claim for hospital outpatient billing. Sample forms can be found at organonaccessprogram-ontruzant.com.

This is a sample CMS-1500 paper claim for office billing. Sample forms can be found at organonaccessprogram-ontruzant.com.

Sample CMS-1500 Claim Form for Office Billing: ONTRUZANT® (trastuzumab-dttb) for Injection, for Intravenous Use 21 mg/mL.

Before prescribing ONTRUZANT, please read the accompanying Prescribing Information, including the Boxed Warning.

Note: For purposes of billing, if a portion of a package is unused, consult the applicable payer policy regarding billing. Record the amount of drug administered and the amount retained in the patient encounter's Medication Report for use in the UB-04 form or all bills that include related charges.

HEALTH INSURANCE CLAIM FORM

Box 19

- Some payers may require drug name, route of administration, NDC, and/or dosage to be provided in Box 19. Check with your payer to verify requirements.

Box 21

- Enter appropriate diagnosis code(s).

Box 24 E

- Record the relevant diagnosis pointer from Box 21.

Box 24 D

- Use C5172 to bill for ONTRUZANT (trastuzumab-dttb).
- The inflation time corresponds to DT code 28112. (Some payers may prefer use of HCPCS. Check with the applicable payer.)

Box 24 G

- Enter the number of units administered in this field.
- On a separate line, enter the appropriate number of units discarded (if applicable) along the JW modifier.
- Note that 1 unit equals 70 mg of ONTRUZANT (trastuzumab-dttb) for DT™.

The regulations contained on this form are compiled from sources believed to be accurate for the Medicare Part B program. Ontruzant makes no representation that the information is accurate or that it will comply with the requirements of the Medicare Part B program. Ontruzant makes no representation that the information is accurate or that it will comply with the requirements of the Medicare Part B program. Ontruzant makes no representation that the information is accurate or that it will comply with the requirements of the Medicare Part B program. Ontruzant makes no representation that the information is accurate or that it will comply with the requirements of the Medicare Part B program.

DIG, US Centers for Medicare & Medicaid Services, HCPCS, Healthcare Common Procedure Coding System, DT, Current Procedural Terminology, DT © 2017 American Medical Association. All rights reserved. DT™ is a registered trademark of the American Medical Association, INC. Medicare, Medicaid and Medicare Supplement.

© 2017 Ontruzant. Paper form and electronic billing information is not for sale.

Before prescribing ONTRUZANT, please read the Selected Safety Information on pages 3-6 and the accompanying Prescribing Information, including the Boxed Warning about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.



Ontruzant®
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL

SELECTED SAFETY INFORMATION



CARDIOMYOPATHY

- Administration of trastuzumab products can result in subclinical and clinical cardiac failure. The incidence and severity was highest in patients receiving a trastuzumab product with anthracycline-containing chemotherapy regimens.
- Evaluate left ventricular function in all patients prior to and during treatment with ONTRUZANT. Discontinue ONTRUZANT treatment in patients receiving adjuvant therapy and withhold ONTRUZANT in patients with metastatic disease for clinically significant decrease in left ventricular function.

INFUSION REACTIONS; PULMONARY TOXICITY

- Administration of trastuzumab products can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration of trastuzumab products. Interrupt ONTRUZANT infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue ONTRUZANT for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.

EMBRYO-FETAL TOXICITY

- Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception.

Before prescribing ONTRUZANT, please read the Selected Safety Information on pages 3-6 and the accompanying [Prescribing Information](#), including the **Boxed Warning** about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.

REFERENCES

1. Cancer, Vision and Other Associated Drugs HCPCS code range Q5112-Q5152. Codify by AAPC. Accessed May 29, 2025. <https://www.aapc.com/codes/hcpcs-codes-range/525/>
2. Medicare program. Discarded drugs and biologicals – JW modifier and JZ modifier policy: frequently asked questions. Centers for Medicare & Medicaid Services. Accessed May 14, 2025. <https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf>
3. Billing and coding: hospital outpatient drugs and biologicals under the Outpatient Prospective Payment System (OPPS). Centers for Medicare & Medicaid Services. March 1, 2018. Updated December 26, 2024. Accessed May 14, 2025. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=55913>
4. Smith AL. CPT coding for drug administration. AAPC Knowledge Center. February 1, 2013. Accessed May 14, 2025. <https://www.aapc.com/blog/23016-infuse-yourself-with-coding-knowledge/?srltid=AfmBOorwmR3tvHxXNK6J1pobHzc6x3lqCn4G BrgFlx--LBUcBUlFO6h>
5. Malignant neoplasm of breast C50-. ICD10Data. Accessed May 14, 2025. <https://www.icd10data.com/ICD10CM/Codes/C00-D49/C50-C50/C50->
6. Malignant neoplasm of stomach C16-. ICD10Data. Accessed May 19, 2025. <https://www.icd10data.com/ICD10CM/Codes/C00-D49/C15-C26/C16->



Dare to move forward.
Our commitment is all in.

© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies. US-SBF-115562 06/25



Ontruzant®
trastuzumab-dttb
for injection, for intravenous use 21 mg/mL